Shares of Eli Lilly (LLY) are soaring in Tuesday's trading session after the company raised its full-year guidance, driven by the surging demand for its offerings. BMO Capital Markets BioPharma Equity Research Managing Director Evan Seigerman joins the Morning Brief to discuss the stock's outlook. Seigerman notes that "demand is off the charts" for the company, and the raised guidance supports the bullish outlook. Despite missing on revenue, the company beat profit expectations, bolstering... Read this story